Literature DB >> 8440929

Fecal antibody responses to symptomatic and asymptomatic rotavirus infections.

D O Matson1, M L O'Ryan, I Herrera, L K Pickering, M K Estes.   

Abstract

The role of anti-rotavirus fecal IgA (RVflgA) in protecting children against natural rotavirus infections is unclear. Rotavirus outbreaks occurred in each of four day care centers attended by 129 children; 42% of the infections were asymptomatic. RVflgA titers were measured by EIA before infection and 4 weeks later in 50 children who excreted rotavirus (excretors) and in two samples 4 weeks apart from 50 children without detected virus excretion (nonexcretors). Forty-three (86%) excretors and 18 (36%) nonexcretors had a fourfold or greater RVflgA titer rise. Preexposure RVflgA titers were higher in not infected than symptomatic (P = .002), asymptomatic than symptomatic (P = .036), and not infected than asymptomatic children (P = .07). RVflgA titers after asymptomatic infections were slightly than after symptomatic infections (P = .087). In summary, higher RVflgA titers were associated with protection against infection and illness and increased fourfold or more in both asymptomatic and symptomatic children.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8440929     DOI: 10.1093/infdis/167.3.577

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  46 in total

1.  Rotavirus Vaccines: Current Controversies and Future Directions.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

2.  Protein Malnutrition Alters Tryptophan and Angiotensin-Converting Enzyme 2 Homeostasis and Adaptive Immune Responses in Human Rotavirus-Infected Gnotobiotic Pigs with Human Infant Fecal Microbiota Transplant.

Authors:  David D Fischer; Sukumar Kandasamy; Francine C Paim; Stephanie N Langel; Moyasar A Alhamo; Lulu Shao; Juliet Chepngeno; Ayako Miyazaki; Huang-Chi Huang; Anand Kumar; Gireesh Rajashekara; Linda J Saif; Anastasia N Vlasova
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

Review 3.  Immune responses to rotavirus infection and vaccination and associated correlates of protection.

Authors:  Ulrich Desselberger; Hans-Iko Huppertz
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

4.  Immune mediators of rotavirus antigenemia clearance in mice.

Authors:  Glendie Marcelin; Amber D Miller; Sarah E Blutt; Margaret E Conner
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

5.  Serotype specificity of the neutralizing-antibody response induced by the individual surface proteins of rotavirus in natural infections of young children.

Authors:  G Menchaca; L Padilla-Noriega; M Méndez-Toss; J F Contreras; F I Puerto; H Guiscafré; F Mota; I Herrera; R Cedillo; O Muñoz; R Ward; Y Hoshino; S López; C F Arias
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

6.  Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus.

Authors:  N Feng; J W Burns; L Bracy; H B Greenberg
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Lymphotoxin alpha-deficient mice clear persistent rotavirus infection after local generation of mucosal IgA.

Authors:  Uri Lopatin; Sarah E Blutt; Margaret E Conner; Brian L Kelsall
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles.

Authors:  S C Chen; D H Jones; E F Fynan; G H Farrar; J C Clegg; H B Greenberg; J E Herrmann
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Group A rotavirus G type prevalence in two regions of Hungary.

Authors:  G Szücs; D O Matson; M Uj; E Kukán; I Mihály; Z Jelenik; M K Estes
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

10.  Heat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector.

Authors:  Yuanmei Ma; Yue Duan; Yongwei Wei; Xueya Liang; Stefan Niewiesk; Michael Oglesbee; Jianrong Li
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.